Commit To Buy Madrigal Pharmaceuticals At $350, Earn 14.6% Annualized Using Options

Madrigal Pharmaceuticals (MDGL) is trading at $478.31 and a January 2027 $350 put can be sold for a $48 premium, which implies a $302 per-share effective cost basis if assigned and a 14.6% annualized return for the put seller. The trade requires a 26.6% decline to be exercised; the article notes the trailing-12-month volatility at 47% and frames the position as premium income with the primary upside limited to collected premium and downside risk of assignment.

Analysis

Market structure: The immediate beneficiary of the described trade is the put seller (and options premium hunters/market-makers) who can lock a 14.6% annualized yield by selling the Jan‑2027 MDGL $350 put; downside goes to the seller if MDGL falls ~26.6% to $350 and assignment occurs. This trade signals available capital looking for yield in biotech and a market that prices material binary risk—47% trailing volatility implies ~25% one‑year probability of hitting the strike (ln(350/478.31)/0.47 ≈ -0.66 → N(-0.66)≈25%). Cross-asset effects are limited but a large IV move in MDGL could lift biotech IV (XBI/IBB) and slightly increase correlations with growth equities and EM FX risk premia.

Risk assessment: Tail risks are classic biotech binaries—trial failure, CRL or safety event—that could drop MDGL >50% (transforming an attractive premium into large realized loss). Timeframes: immediate (days) expect vega and skew moves; short term (weeks–months) monitor IV and any 12‑month catalysts; long term (≥1 year) fundamentals and approval outcomes drive realized return. Hidden dependencies include options liquidity and assignment timing (capital gets tied up), and ETF flows that can amplify moves. Key catalysts: clinical readouts, FDA interactions, and M&A rumors within the next 6–12 months.

Trade implications: For yield-seeking cash‑secure sellers, the Jan‑2027 $350 put is a defined exposure: collect premium ≈ $48 (cost basis if assigned $302/share) with ~25% modeled exercise chance; size to 1–2% of portfolio and cap upside by predefining max assignment risk. If bullish on MDGL’s fundamentals, prefer buying shares or a buy‑write (own stock and sell calls) to retain upside; if cautious, use a put‑sell + protective long put (put spread) to cap tail. Relative play: long MDGL equity vs short XBI (20–40% notional) to isolate idiosyncratic outcome while hedging sector risk.

Contrarian angles: Consensus underweights the cost of lost upside for put sellers—collecting $48 forfeits direct upside above $350; if MDGL rallies >20% in 12 months, short put sellers miss large gains. The market may be underpricing regulatory binary (implied exercise chance ~25% vs subjective higher risk for late‑stage assets); historical parallels (biotech post‑readout volatility) suggest skew can invert quickly, creating buybacks at cheaper levels. Unintended consequence: concentrated put selling can create forced stock purchases on assignment, raising short‑term demand and compressing realized volatility temporarily.

Key Decisions for Investors

• Sell cash‑secured Jan‑2027 MDGL $350 puts sized to 1% of portfolio notional (max assignment exposure = 1% * portfolio), collect ~ $48 premium; close if MDGL trades below $400 or if option IV rises >30% from current level to limit path risk.
• If bullish on fundamentals, establish a 1–2% long position in MDGL equity on a pullback ≥20% (target entry ≤ $382) or implement a buy‑write: buy shares and sell Jan‑2027 $500 calls to monetize upside while capping at strike.
• Construct a hedged premium trade: sell the Jan‑2027 $350 put and simultaneously buy the $250 put (put spread) to cap downside; size to 2% portfolio with max loss defined as ($350‑$250‑net premium) per share.
• Implement a relative value pair: long MDGL stock 1% vs short XBI 0.25–0.5% (notional ratio 2:1–4:1) to express idiosyncratic upside while hedging sector drawdowns; rebalance monthly and tighten if XBI outperforms by >10% in 30 days.
• Monitor catalysts: re‑evaluate positions 90 and 30 days before any scheduled MDGL clinical/FDA milestones and liquidate or hedge if implied IV compresses >40% or if trial readouts are announced within the next 6–12 months.